Insulin resistance and cardiometabolic diseases: new perspective from basic to clinical research

Dear Colleagues,

Insulin resistance is defined by suboptimal cellular response to physiological levels of insulin in diverse tissues, including liver, muscle, and adipose tissue. Insulin resistance impairs glucose disposal, resulting in a compensatory hyperinsulinemia. The metabolic consequences of insulin resistance can result in hyperglycemia, dyslipidemia, hypertension, visceral adiposity, elevated inflammatory markers, endothelial dysfunction, and a prothrombic state. Therefore, insulin resistance plays an important role in the pathophysiology of cardiometabolic diseases.

It has been documented that multiple clinical and subclinical disease phenotypes are associated with insulin resistance, i.e. diabetes mellitus, prediabetes, obesity, metabolic syndrome, non-alcoholic fatty liver. Multiple laboratory indexes, including triglyceride–glucose index, homeostatic model assessment of insulin resistance (HOMA-IR) were used to define insulin resistance. So far, however, the underlying pathophysiological mechanisms of insulin resistance and its interplay between the cardiometabolic diseases remain to be further investigated.

In this special issue, we would like to create a forum for lifestyle and genetic factors for insulin resistance; cellular and physiological mechanisms that link insulin resistance, metabolic syndrome and cardiovascular disease; pathophysiological and clinical consequences of insulin resistance, particularly relation to cardiovascular disease, stroke, chronic kidney disease. We welcome manuscripts focusing on the molecular mechanisms involved in the development of insulin resistance and cardiovascular diseases. We also expect clinical or experimental studies evaluating the effects of potential therapeutics against insulin resistance and metabolic syndrome in cardiovascular diseases.

Topics of interest includes but are not limited to: 1. Prevention and treatment options for insulin resistance and metabolic syndrome, which consequentially benefit in prevention of cardiometabolic disease; 2. The molecular mechanisms involved in the development of insulin resistance and metabolic pathways in cardiometabolic diseases, especially for hypertension, diabetes, coronary heart disease, stroke, chronic kidney disease and heart failure.

Prof. Jie Shen, Prof. Yunzhao Hu, Prof. Jie Yu and Prof. Yuli Huang

Guest Editors

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.